First Illinois patient successfully treated in TREVO 2 study

174

Central DuPage Hospital, Winfield, Illinois, USA, has enrolled and successfully treated the first patient in Illinois in the TREVO 2 study that seeks to evaluate the Trevo retrieval system (Concentric Medical), a novel device for removing clots from the brain in patients experiencing an acute ischaemic stroke. 

The procedure was performed by Harish Shownkeen, interventional neuroradiologist, co-medical director of the Stroke & Neurovascular Programme. He said, “I am extremely pleased with the patient’s outcome. Participating in trials like TREVO 2 is very important to my team as we continue to expand our stroke toolkit.”


The TREVO 2 study (Thrombectomy revascularization of large vessel occlusions in acute ischemic stroke) is a randomised, multicentre, prospective trial approved by the Food and Drug Administration (FDA) to evaluate the Trevo retrieval system. TREVO 2 is designed to assess the ability of the Trevo system to remove the blood clots that cause strokes and to restore blood flow to the brain. Functional outcomes at 90 days will be collected and analysed. 

(Visited 9 times, 1 visits today)